Grape King Bio Ltd (TPE:1707)

Market Cap	18.07B -16.2%
Revenue (ttm)	10.40B -7.2%
Net Income	1.22B -17.0%
EPS	8.19 -16.8%
Shares Out	148.14M
PE Ratio	14.89
Forward PE	13.28
Dividend	6.40 (5.25%)
Ex-Dividend Date	Jan 8, 2026

Volume	90,982
Average Volume	105,594
Open	123.50
Previous Close	122.50
Day's Range	121.50 - 123.50
52-Week Range	119.50 - 151.50
Beta	0.38
RSI	45.59
Earnings Date	Feb 23, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.